Compare Repligen Corporation Common Stock (RGEN) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Tyson Foods, Inc. — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Tyson Foods, Inc. trades at $54.25 (market cap $18.92B). The key difference: Tyson Foods, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.79% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Tyson Foods, Inc. for 77 Days on average.
| RGEN | TSN | |
|---|---|---|
Market Cap | $11.14B | $18.92B |
Volume | 1,259,263 | 2,968,585 |
Sector | Health | Consumer Staples |
52-Week High | $194.57 | $68.75 |
52-Week Low | $102.87 | $50.47 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $11.02B | $26.19B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Tyson Foods (TSN) trades at $54.22, up 1.21% with a bullish technical signal despite recent volatility. The stock shows mixed earnings performance with two beats and one miss in recent quarters, while maintaining a 53% analyst buy rating. Current valuation metrics include a P/E of 33.2 and P/S of 0.34, with revenue growth projected to $55.7B in 2026. Recent corporate actions include consistent dividend payments of $0.51 per share.
Outlook remains cautiously optimistic with a $65.40 consensus price target representing 21% upside potential. Key risks include ongoing beef segment losses, securities investigations, and margin pressure. The company's ability to maintain dividends while addressing operational challenges will be critical for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
